General public

What is BLUE CORAL?

The BLUE CORAL study is a research study that is collecting information to learn more about SARS-CoV-2, the virus that causes COVID-19, and how to better care for people who are sick from COVID-19.

Who can be in this study?

Adults admitted to the hospital within 14 days of a test positive for SARS-CoV-2, the virus that causes COVID-19 and have symptoms of the virus (fever, cough, or trouble breathing) may be eligible for the study. Only hospitals that are part of the PETAL Network can enroll subjects.

What Happens in this study?

• Information will be collected from study participants’ medical records and by asking them questions during the time they are in the hospital and in the first month after they leave the hospital
• Some additional blood tests may be performed
• Some participants may be asked for permission to collect additional blood for future studies to learn more about COVID-19
• Some participants may be contacted after they leave the hospital to see how they and doing and feeling

Who is paying for this study?

The National Heart, Lung and Blood Institute (NHLBI), which is part of the U.S. government, is paying for this research.

Trial Summary:

Purpose:

BLUE CORAL is a detailed prospective cohort study of patients hospitalized with acute SARS-CoV2 infection at PETAL Network hospitals. The primary objective of BLUE CORAL is to describe the clinical characteristics, treatments, biology and outcomes of 1500 hospitalized patients with Covid-19. In addition to all hospital data collected in RED CORAL, BLUE CORAL adds (1) in-hospital surveys detailing premorbid function, (2) biospecimen collection, and (3) centralized post-hospital telephone follow-up at 1, 3 and 6 months after hospital discharge.

Study Design:

Observational study of hospitalized patients with COVID-19

Primary Objectives

Describe the clinical characteristics, treatments, biology, and outcomes of hospitalized patients with COVID-19

Secondary Objectives

• Identify clinical and biologic risk factors and create prediction models for COVID-19 outcomes, including acute respiratory failure, prolonged mechanical ventilation, cardiomyopathy, and death
• Create a deidentified repository of clinical, imaging, and biologic data and of biospecimens for rapid sharing with the scientific community

Study Size:

This study will enroll up to 1500 people hospitalized due to COVID-19 infection.